Seres Therapeutics Inc. (NASDAQ:MCRB) shares traded -0.18% lower at $5.60 on Wall Street last session.
In accordance with the data, 8 analysts cover Seres Therapeutics Inc. (NASDAQ:MCRB). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $25.00 and a low of $4.00, we find $12.00. Given the previous closing price of $5.61, this indicates a potential upside of 113.9 percent. MCRB stock price is now -16.32% away from the 50-day moving average and 1.86% away from the 200-day moving average. The market capitalization of the company currently stands at $698.99M.
It has been rated a hold by 0 analysts and a buy by 7. Brokers who have rated the stock have averaged $13.43 as their price target over the next twelve months.
With the price target reduced from $24 to $7, Goldman Downgraded its rating from Neutral to Sell for Seres Therapeutics Inc. (NASDAQ: MCRB). , while ‘Chardan Capital Markets’ rates the stock as ‘Buy’.
In other news, Ege David S., insider sold 5,012 shares of the company’s stock on Oct 31. The stock was sold for $39,745 at an average price of $7.93. Upon completion of the transaction, the insider now directly owns 46,734 shares in the company, valued at $0.26 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jul 05, 10% Owner Nutritional Health LTP Fund Ge bought 8,738,243 shares of the business’s stock. A total of $27,525,465 was incurred on buying the stock at an average price of $3.15. This leaves the insider owning 5,875,711 shares of the company worth $32.9 million. Insiders disposed of 5,012 shares of company stock worth roughly $28067.199999999997 over the past 1 year. A total of 0.50% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in MCRB stock. A new stake in Seres Therapeutics Inc. shares was purchased by EVERSEPT PARTNERS, LP during the first quarter worth $10,841,000. RAFFERTY ASSET MANAGEMENT, LLC invested $1,146,000 in shares of MCRB during the first quarter. In the first quarter, CLARIVEST ASSET MANAGEMENT LLC acquired a new stake in Seres Therapeutics Inc. valued at approximately $657,000. KNOTT DAVID M JR acquired a new stake in MCRB for approximately $616,000. EDGEWOOD MANAGEMENT LLC purchased a new stake in MCRB valued at around $560,000 in the second quarter. In total, there are 188 active investors with 85.80% ownership of the company’s stock.
Seres Therapeutics Inc. (NASDAQ: MCRB) opened at $5.54 on Friday. During the past 12 months, Seres Therapeutics Inc. has had a low of $2.50 and a high of $9.49. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 3.00, and a quick ratio of 3.00. The fifty day moving average price for MCRB is $6.68 and a two-hundred day moving average price translates $5.49 for the stock.
The latest earnings results from Seres Therapeutics Inc. (NASDAQ: MCRB) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.7, missing analysts’ expectations of -$0.6 by -0.1. This compares to $0.72 EPS in the same period last year. The company reported revenue of $3.44 million for the quarter, compared to $126.72 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -97.28 percent. For the current quarter, analysts expect MCRB to generate $7M in revenue.
Seres Therapeutics Inc.(MCRB) Company Profile
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company’s lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.